Literature DB >> 24837472

Hyperactivity, concentration difficulties and impulsiveness improve during seven weeks' treatment with valerian root and lemon balm extracts in primary school children.

Jürgen Gromball1, Frank Beschorner2, Christian Wantzen3, Ute Paulsen4, Martin Burkart5.   

Abstract

BACKGROUND: Valerian root and lemon balm extracts have previously shown efficacy and excellent tolerability in children<12 years suffering from restlessness and insomnia. We now examined whether treatment with a fixed combination of both may also improve concentration, hyperactivity and impulsiveness.
METHODS: 169 primary school children suffering from hyperactivity and concentration difficulties but not meeting ADHS criteria were treated in an observational study by 27 office based pediatricians with a recommended daily dose of 640 mg valerian root extract WS(®) 1014 and 320 mg lemon balm extract WS(®) 1303 (Sandrin(®)), and evaluated by pediatricians and parents using standardized questionnaires at baseline, weeks 2 and 7.
RESULTS: The fraction of children having strong/very strong symptoms of poor ability to focus decreased from 75% to 14%, hyperactivity from 61% to 13%, and impulsiveness from 59% to 22%. Parent rated social behavior, sleep and symptom burden showed highly significant improvements. Only in two children mild transient adverse drug reactions were observed.
CONCLUSION: In primary school children with restlessness, concentration difficulties and impulsiveness treatment with WS(®) 1014 and WS(®) 1303 (Sandrin(®)) provides a viable option in addition to counseling and education.
Copyright © 2014. Published by Elsevier GmbH.

Entities:  

Keywords:  Concentration deficit; Hyperactivity; Melissa; Primary school children; Valerian-lemon balm-extract; Valeriana

Mesh:

Substances:

Year:  2014        PMID: 24837472     DOI: 10.1016/j.phymed.2014.04.004

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  3 in total

1.  The effect of Rosa canina L. and a polyherbal formulation syrup in patients with attention-deficit/hyperactivity disorder: a study protocol for a multicenter randomized controlled trial.

Authors:  Haide Golsorkhi; Mostafa Qorbani; Mohammad Kamalinejad; Saeideh Sabbaghzadegan; Mohsen Bahrami; Mohammad Vafaee-Shahi; Hadi Montazerlotfelahi; Elham Abniki; Majid Dadmehr
Journal:  Trials       Date:  2022-05-23       Impact factor: 2.728

2.  Whey Protein (Ma'aljobon) as a Complementary Therapy for Treatment of Attention-deficit/ Hyperactivity Disorder (ADHD): A Randomized Open-label Controlled Clinical Trial.

Authors:  Zeinab Mostajeran; Seyed Hamdollah Mosavat; Mostafa Najafi; Majid Emtiazy; Mohammad Hashem Hashempur
Journal:  Galen Med J       Date:  2020-08-27

Review 3.  Potential Novel Therapies for Neurodevelopmental Diseases Targeting Oxidative Stress.

Authors:  Alexandrina S Curpan; Alina-Costina Luca; Alin Ciobica
Journal:  Oxid Med Cell Longev       Date:  2021-07-22       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.